Get the Stockscreener App
18.44
2.50%
0.45
After Hours:
18.54
0.10
+0.54%
Bausch Lomb Corp stock is traded at $18.44, with a volume of 507.36K.
It is up +2.50% in the last 24 hours and up +8.60% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$17.99
Open:
$18.1
24h Volume:
507.36K
Relative Volume:
1.33
Market Cap:
$6.53B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-23.84
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
+4.00%
1M Performance:
+8.60%
6M Performance:
+23.43%
1Y Performance:
+16.64%
1-Day Range:
$18.10
$18.64
1-Week Range:
$16.25
$18.64
52-Week Range:
$10.45
$18.64
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
18.44 | 6.37B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
494.02 | 174.76B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.49 | 52.44B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
84.13 | 40.70B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
49.99 | 40.28B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
251.63 | 37.99B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Is It Time To Reassess Bausch + Lomb (BLCO) After Its Recent Share Price Strength? - Yahoo Finance
Bausch + Lomb Corporation - Baystreet.ca
H.C. Wainwright raises Bausch & Lomb stock price target to $20 By Investing.com - Investing.com Australia
H.C. Wainwright raises Bausch & Lomb stock price target to $20 - Investing.com UK
Digital lifestyles are turning eyes red – and one drop stands out - Stock Titan
Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS) - GlobeNewswire Inc.
Adding B Vitamins To AREDS Has Bausch + Lomb Seeing Consumer Health Sales Boost Ahead - Citeline News & Insights
Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook - Insider Monkey
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $20 - 富途牛牛
Will Bausch Lomb Corporation outperform its industry peers2025 Trade Ideas & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Stifel raises Bausch & Lomb stock price target on strong Miebo sales - Investing.com South Africa
Deutsche Bank Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $18 - 富途牛牛
Bausch + Lomb price target raised to $15 from $13 at BofA - TipRanks
Breaking Down Bausch & Lomb: 6 Analysts Share Their Views - Benzinga
Bausch + Lomb price target raised to $21 from $20 at Citi - TipRanks
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $18 - 富途牛牛
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2025 Earnings Call Transcript - Insider Monkey
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $15 to $21 - 富途牛牛
Needham Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating - 富途牛牛
Beyond the Balance Sheet: What SWOT Reveals About Bausch & Lomb Corp (BLCO) - GuruFocus
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus - Yahoo Finance
Bausch + Lomb Signals Profitable Growth After Record Year - TipRanks
Bausch + Lomb stock hits 52-week high at $17.87 By Investing.com - Investing.com Australia
Bausch + Lomb Lifts 2025 Revenue on Dry Eye and Vision Care Growth - TipRanks
Bausch + Lomb Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Top News Today/Canada: Bausch + Lomb Sets 2026 Forecast - 富途牛牛
Bausch & Lomb Earnings: Nice Results from Growth Momentum, Solid Execution, and Pipeline Investment - Morningstar Canada
Bausch & Lomb Looks for Long-Term Growth Fueled by Innovation and Pipeline Investments - Morningstar
1st contact lens innovation since 1999 is coming: Bausch + Lomb CEO - Yahoo Finance
Why Bausch + Lomb's CEO is tying paychecks to AI literacy - Yahoo Finance
Bausch + Lomb Q4 Earnings Call Highlights - Yahoo Finance
Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Bausch + Lomb (BLCO) Lags Q4 Earnings Estimates - Yahoo Finance
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue - Yahoo Finance
Bausch + Lomb shares edge higher despite earnings miss as revenue tops estimates - Investing.com
Bausch + Lomb Q4 and Full-Year 2025 Financial Results - TradingView
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance - The AI Journal
Bausch & Lomb Corp (BLCO) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
Stifel raises Bausch & Lomb stock price target on Miebo strength By Investing.com - Investing.com Nigeria
Stifel raises Bausch & Lomb stock price target on Miebo strength - Investing.com Nigeria
Bausch + Lomb stock hits 52-week high at $17.87 - Investing.com
Bausch + Lomb earnings on deck as Miebo profitability looms - Investing.com
Bausch + Lomb earnings on deck as Miebo profitability looms By Investing.com - Investing.com Nigeria
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect - Yahoo Finance
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):